期刊
JOURNAL OF CONTROLLED RELEASE
卷 144, 期 2, 页码 233-241出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2010.02.006
关键词
Inhalation; Nanostructured lipid carrier; Celecoxib; Lung cancer; Lung disposition
资金
- NIH [G12RR03020-11]
The aim of the current study was to encapsulate celecoxib (Cxb) in the nanostructured lipid carrier (Cxb-NLC) nanoparticles and evaluate the lung disposition of nanoparticles following nebulization in Balb/c mice. Cxb-NLC nanoparticles were prepared with Cxb, Compritol, Miglyol and sodium taurocholate using high-pressure homogenization. Cxb-NLC nanoparticles were characterized for physical and aerosol properties. In-vitro cytotoxicity studies were performed with A549 cells. The lung deposition and pharmacokinetic parameters of Cxb-NLC and Cxb solution (Cxb-Soln) formulations were determined using the Inexpose (TM) system and Pan LC star jet nebulizer. The particle size and entrapment efficiency of the Cxb-NLC formulation were 217 +/- 20 nm and >90%, respectively. The Cxb-NLC released the drug in controlled fashion, and in-vitro aerosolization of Cxb-NLC formulation showed an FPF of 75.6 +/- 4.6%, MMAD of 1.6 +/- 0.13 mu m and a GSD of 1.2 +/- 0.21. Cxb-NLC showed dose and time dependent cytotoxicity against A549 cells. Nebulization of Cxb-NLC demonstrated 4 fold higher AUC(t)/D in lung tissues compared to the Cxb-Soln. The systemic clearance of Cxb-NLC was slower (0.93 l/h) compared to the Cxb-Soln (20.03 l/h). Cxb encapsulated NLC were found to be stable and aerodynamic properties were within the respirable limits. Aerosolization of Cxb-NLC improved the Cxb pulmonary bioavailability compared to solution formulation which will potentially lead to better patient compliance with minimal dosing intervals. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据